

Supplementary Material for

Exploring *N*-acyl-4-azatetracyclo[5.3.2.0^{2,6}.0^{8,10}]dodec-11- enes as 11 β -HSD1 inhibitors

Rosana Leiva^a, Andrew McBride^b, Margaret Binnie^b, Scott P. Webster^b,
and Santiago Vázquez^{a,*}



^a *Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, Barcelona, E-08028, Spain*



^b *Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, EH16 4TJ, United Kingdom*



INDEX



¹ H and ¹³ C NMR spectra of 4	S3
¹ H and ¹³ C NMR spectra of 5	S5
¹ H and ¹³ C NMR spectra of 6	S7
¹ H and ¹³ C NMR spectra of 7	S9
¹ H and ¹³ C NMR spectra of 8	S11
¹ H and ¹³ C NMR spectra of 9	S13
¹ H and ¹³ C NMR spectra of 10	S15
¹ H and ¹³ C NMR spectra of 11	S17
¹ H and ¹³ C NMR spectra of 12	S19
¹ H and ¹³ C NMR spectra of 13	S21
¹ H and ¹³ C NMR spectra of 14	S23
¹ H and ¹³ C NMR spectra of 15	S25
¹ H and ¹³ C NMR spectra of 16	S27


4











f1 (ppm)

S7

